Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467840 · ClinicalTrials.gov registry record · Phase 2
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A Phase 2 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 475
- Enrollment target
NCT04467840: Completed Phase 2 study, sponsored by RedHill Biopharma Limited.
NCT04467840 is a Phase 2 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 475 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (257% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04467840, a Phase 2 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 475 participants
- Enrollment target
Study Summary
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.
Primary Outcome
To compare the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14 between subjects taking opaganib and those on placebo.
Interventions
- DRUG Placebo
- DRUG Opaganib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2021-07-18 |
| Phase | Phase 2 |
What the finished NCT04467840 record still lists
NCT04467840 is an interventional study that assigns participants to a tested intervention. The registered 475 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (257% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04467840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04467840 about?
NCT04467840 is a clinical study titled "Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia". A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.
What is the current status of trial NCT04467840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 475 participants. The study started on 2020-08-21. Estimated completion is 2021-07-18.
What interventions are being tested in trial NCT04467840?
The interventions under investigation include: Placebo (DRUG), Opaganib (DRUG).
Who is sponsoring clinical trial NCT04467840?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04467840's enrollment target sits among peer trials
475 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
- NCT05451303 · 475 participants
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
- NCT06892379 · 475 participants · Phase 1
A Study of HS-20110 in Participants With Advanced Solid Tumors
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI